Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

This study has been terminated.
(Difficulty in recruiting)
Human Genome Center, Institute of Medical Science, University of Tokyo
Information provided by:
Tokyo University Identifier:
First received: May 12, 2008
Last updated: December 28, 2009
Last verified: May 2009
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2009
  Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)